# MYOD1

## Overview
MYOD1 is a gene that encodes the myogenic differentiation 1 protein, a pivotal transcription factor in the regulation of muscle differentiation. The protein belongs to the myogenic regulatory factor (MRF) family and is characterized by a basic helix-loop-helix (bHLH) motif, which is crucial for its function in DNA binding and dimerization with other proteins, such as E2A, to regulate muscle-specific gene expression (Tapscott1991MyoD). MYOD1 plays a significant role in the activation and proliferation of myogenic satellite cells, which are essential for muscle growth and repair (Zhang2010Activation). The gene's expression is tightly regulated, and its activity is primarily localized in the nucleus of muscle precursor cells, where it influences muscle development and regeneration (Zhang2010Activation). Mutations in MYOD1 have been linked to various pathological conditions, including rhabdomyosarcoma, highlighting its clinical significance (Agaram2014Recurrent).

## Structure
The MYOD1 protein is a key transcription factor involved in muscle differentiation, characterized by its basic helix-loop-helix (bHLH) motif. This motif is essential for DNA binding and dimerization, consisting of two amphipathic alpha-helices separated by a nonhelical loop (Tapscott1991MyoD). The basic region of the bHLH domain interacts directly with DNA, while the helix-loop-helix structure facilitates protein-protein interactions, allowing MYOD1 to form heterodimers with E2A proteins, which enhances its DNA binding affinity (Tapscott1991MyoD).

The NH2-terminal region of MYOD1 likely functions as a transcriptional activation domain, while the COOH-terminal region may be involved in chromatin remodeling, providing access to silenced muscle genes (Ishibashi2005MyoD). Specific domains within MYOD1, such as the cysteine/histidine-rich (C/H) region and the C-terminal domain, have been identified as critical for its regulatory function. Monoclonal antibodies have been used to map these regions, pinpointing epitopes between residues 63-99 and 168-318 (Cole1992Monoclonal).

Post-translational modifications, such as phosphorylation, have been observed in MYOD1, although they do not significantly change during C2C12 differentiation, suggesting other regulatory mechanisms may be at play (Cole1992Monoclonal).

## Function
MYOD1, a myogenic regulatory factor, plays a crucial role in muscle differentiation by regulating the transcription of muscle-specific genes. It binds to E-box sequences in DNA, facilitating the transcription of genes necessary for muscle cell lineage commitment and differentiation (Zhang2010Activation). MYOD1 is involved in the activation and proliferation of quiescent myogenic satellite cells, essential for muscle growth and repair. It is required for the induction of Cdc6, a key factor in preparing chromatin for DNA replication, which is crucial for the transition of quiescent myoblasts into the S phase of the cell cycle (Zhang2010Activation).

In the absence of MYOD1, other factors like Myf5 can partially compensate, indicating a degree of functional redundancy in myogenesis (Zhang2010Activation). MYOD1 also interacts with other transcription factors, such as E2F3a, to regulate the expression of genes involved in DNA replication and cell cycle progression, highlighting its role in the proliferative expansion of adult myogenic stem cells (Zhang2010Activation). MYOD1's activity is primarily localized in the nucleus of muscle precursor cells, where it influences muscle development and regeneration (Zhang2010Activation).

## Clinical Significance
Mutations in the MYOD1 gene are associated with several severe conditions. A novel nonsense mutation in MYOD1 has been linked to lethal fetal akinesia deformation sequence (FADS), a condition characterized by fetal akinesia, intrauterine growth retardation, arthrogryposis, and developmental anomalies, leading to death due to pulmonary hypoplasia. This mutation disrupts the gene's role in muscle development, marking the first association of MYOD1 mutations with a human disease phenotype (Watson2016Deficiency).

MYOD1 mutations, particularly the p.L122R mutation, are also implicated in rhabdomyosarcoma (RMS), a type of cancer. This mutation is prevalent in both pediatric and adult cases of spindle cell and sclerosing RMS, where it is associated with aggressive clinical behavior and poor prognosis. The p.L122R mutation affects the DNA-binding domain of MYOD1, conferring MYC-like properties that drive oncogenesis by inhibiting differentiation and promoting proliferation (Agaram2014Recurrent; Choo2022Functional; Agaram2019MYOD1mutant). MYOD1 mutations in RMS are often accompanied by other genetic alterations, such as mutations in the PIK3CA gene, which may further impact the disease's aggressiveness and patient outcomes (Agaram2019MYOD1mutant; Di2023Biological).

## Interactions
MYOD1, a key transcription factor in muscle differentiation, interacts with several proteins and nucleic acids to regulate gene expression. It forms heterodimers with E12/E47, which are crucial for binding to E-box sequences in DNA, thereby promoting muscle-specific gene expression (Abu1998Degradation). MYOD1 also interacts with the BMAL1:CLOCK complex, co-localizing within myonuclei to modulate circadian rhythms in muscle tissue. This interaction is essential for the regulation of genes like Titin-cap (Tcap), where MYOD1 and BMAL1:CLOCK synergistically enhance circadian expression through tandem E-box elements in the Tcap promoter (Hodge2019MYOD1).

MYOD1's interaction with β-catenin is another significant aspect, where β-catenin enhances MYOD1's binding to E-box elements, crucial for muscle differentiation. This interaction is independent of TCF/LEF elements, indicating a distinct mechanism (Kim2008β-Catenin). Additionally, MYOD1 is involved in a transcriptional feed-forward loop with the molecular clock, enhancing circadian amplitude and potentially interacting with accessory clock factors like RORa and Rev-erba (Hodge2019MYOD1). These interactions highlight MYOD1's role as a critical co-factor in transcriptional regulatory complexes governing muscle differentiation and circadian gene expression.


## References


[1. (Agaram2019MYOD1mutant) Narasimhan P. Agaram, Michael P. LaQuaglia, Rita Alaggio, Lei Zhang, Yumi Fujisawa, Marc Ladanyi, Leonard H. Wexler, and Cristina R. Antonescu. Myod1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. a reappraisal for molecular classification and risk stratification. Modern Pathology, 32(1):27–36, January 2019. URL: http://dx.doi.org/10.1038/s41379-018-0120-9, doi:10.1038/s41379-018-0120-9. This article has 131 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41379-018-0120-9)

[2. (Abu1998Degradation) Ossama Abu Hatoum, Shlomit Gross-Mesilaty, Kristin Breitschopf, Aviad Hoffman, Hedva Gonen, Aaron Ciechanover, and Eyal Bengal. Degradation of myogenic transcription factor myod by the ubiquitin pathway in vivo and in vitro: regulation by specific dna binding. Molecular and Cellular Biology, 18(10):5670–5677, October 1998. URL: http://dx.doi.org/10.1128/mcb.18.10.5670, doi:10.1128/mcb.18.10.5670. This article has 98 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.18.10.5670)

[3. (Kim2008β-Catenin) Chang-Hoon Kim, Hannah Neiswender, Eun Joo Baik, Wen C. Xiong, and Lin Mei. Β-catenin interacts with myod and regulates its transcription activity. Molecular and Cellular Biology, 28(9):2941–2951, May 2008. URL: http://dx.doi.org/10.1128/mcb.01682-07, doi:10.1128/mcb.01682-07. This article has 114 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.01682-07)

[4. (Cole1992Monoclonal) Francesca Cole, Kimberly S. Timo, and D. Stave Kohtz. Monoclonal antibodies identify a possible regulatory domain of myod1. Journal of Cellular Biochemistry, 50(2):130–142, October 1992. URL: http://dx.doi.org/10.1002/jcb.240500204, doi:10.1002/jcb.240500204. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.240500204)

[5. (Tapscott1991MyoD) S J Tapscott and H Weintraub. Myod and the regulation of myogenesis by helix-loop-helix proteins. Journal of Clinical Investigation, 87(4):1133–1138, April 1991. URL: http://dx.doi.org/10.1172/jci115109, doi:10.1172/jci115109. This article has 103 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci115109)

[6. (Agaram2014Recurrent) Narasimhan P. Agaram, Chun‐Liang Chen, Lei Zhang, Michael P. LaQuaglia, Leonard Wexler, and Cristina R. Antonescu. Recurrent myod1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. Genes, Chromosomes and Cancer, 53(9):779–787, May 2014. URL: http://dx.doi.org/10.1002/gcc.22187, doi:10.1002/gcc.22187. This article has 126 citations.](https://doi.org/10.1002/gcc.22187)

[7. (Di2023Biological) Daniela Di Carlo, Julia Chisholm, Anna Kelsey, Rita Alaggio, Gianni Bisogno, Veronique Minard-Colin, Meriel Jenney, Raquel Dávila Fajardo, Johannes H. M. Merks, Janet M. Shipley, and Joanna L. Selfe. Biological role and clinical implications of myod1l122r mutation in rhabdomyosarcoma. Cancers, 15(6):1644, March 2023. URL: http://dx.doi.org/10.3390/cancers15061644, doi:10.3390/cancers15061644. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers15061644)

[8. (Zhang2010Activation) Keman Zhang, Jingfeng Sha, and Marian L. Harter. Activation of cdc6 by myod is associated with the expansion of quiescent myogenic satellite cells. Journal of Cell Biology, 188(1):39–48, January 2010. URL: http://dx.doi.org/10.1083/jcb.200904144, doi:10.1083/jcb.200904144. This article has 70 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1083/jcb.200904144)

[9. (Hodge2019MYOD1) Brian A Hodge, Xiping Zhang, Miguel A Gutierrez-Monreal, Yi Cao, David W Hammers, Zizhen Yao, Christopher A Wolff, Ping Du, Denise Kemler, Andrew R Judge, and Karyn A Esser. Myod1 functions as a clock amplifier as well as a critical co-factor for downstream circadian gene expression in muscle. eLife, February 2019. URL: http://dx.doi.org/10.7554/elife.43017, doi:10.7554/elife.43017. This article has 49 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.43017)

[10. (Choo2022Functional) Florence Choo, Igor Odintsov, Kevin Nusser, Katelyn S. Nicholson, Lara Davis, Christopher L. Corless, Linda Stork, Romel Somwar, Marc Ladanyi, Jessica L. Davis, and Monika A. Davare. Functional impact and targetability of pi3kca, gnas, and pten mutations in a spindle cell rhabdomyosarcoma with myod1 l122r mutation. Molecular Case Studies, 8(1):a006140, January 2022. URL: http://dx.doi.org/10.1101/mcs.a006140, doi:10.1101/mcs.a006140. This article has 9 citations.](https://doi.org/10.1101/mcs.a006140)

[11. (Ishibashi2005MyoD) Jeff Ishibashi, Robert L. Perry, Atsushi Asakura, and Michael A. Rudnicki. Myod induces myogenic differentiation through cooperation of its nh2- and cooh-terminal regions. The Journal of Cell Biology, 171(3):471–482, November 2005. URL: http://dx.doi.org/10.1083/jcb.200502101, doi:10.1083/jcb.200502101. This article has 135 citations.](https://doi.org/10.1083/jcb.200502101)

[12. (Watson2016Deficiency) Christopher M Watson, Laura A Crinnion, Helen Murphy, Melanie Newbould, Sally M Harrison, Carolina Lascelles, Agne Antanaviciute, Ian M Carr, Eamonn Sheridan, David T Bonthron, and Audrey Smith. Deficiency of the myogenic factor myod causes a perinatally lethal fetal akinesia. Journal of Medical Genetics, 53(4):264–269, January 2016. URL: http://dx.doi.org/10.1136/jmedgenet-2015-103620, doi:10.1136/jmedgenet-2015-103620. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmedgenet-2015-103620)